A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC.
Navid F, et al. Among authors: bahrami a.
Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.
Int J Cancer. 2017.
PMID: 28631382
Free PMC article.
Clinical Trial.